Search results for " Multiple"

showing 10 items of 903 documents

Total Hemi-overgrowth in Pigmentary Mosaicism of the (Hypomelanosis of) Ito Type: Eight Case Reports.

2016

Abstract Pigmentary mosaicism of the (hypomelanosis of) Ito type is an umbrella term, which includes phenotypes characterized by mosaic hypopigmentation in the form of streaks, whorls, patchy, or more bizarre skin configurations (running along the lines of Blaschko): these cutaneous patterns can manifest as an isolated skin disorder (pigmentary mosaicism of the Ito type) or as a complex malformation syndrome in association with extracutaneous anomalies (most often of the musculoskeletal and/or nervous systems) (hypomelanosis of Ito). Affected individuals are anecdotally reported to have also partial or total body hemi-overgrowth (HOG), which often causes moderate to severe complications. We…

0301 basic medicineModerate to severeAdultMalePathologymedicine.medical_specialtyAdolescentDevelopmental DisabilitiesContext (language use)030105 genetics & heredity03 medical and health sciences0302 clinical medicinemedicineHumansAbnormalities MultipleClinical Case ReportClinical phenotypeChildKyphoscoliosisPigmentation disorderHypopigmentationChromosome AberrationsHypopigmentationbusiness.industryMosaicismFollow up studiesTotal bodyGeneral Medicinemedicine.diseaseMagnetic Resonance Imaging6200Musculoskeletal Abnormalitieshypomelanosis Ito type Pigmentary mosaicism mosaic hypopigmentation childrenPhenotypeItalyChild PreschoolKaryotypingFemalemedicine.symptombusinessPigmentation Disorders030217 neurology & neurosurgeryResearch ArticleFollow-Up StudiesMedicine
researchProduct

Cytotoxicity of 18 Cameroonian medicinal plants against drug sensitive and multi-factorial drug resistant cancer cells

2018

Abstract Ethnopharmacological relevance Cameroonian medicinal plants are traditionally used to treat many ailments, including cancer and related diseases. Cancer is characterized as a condition with complex signs and symptoms. It has been recommended that ethnopharmacological usages such as immune and skin disorders, inflammatory, infectious, parasitic and viral diseases should be taken into account when selecting plants for anticancer screenings, since these reflect disease states bearing relevance to cancer or cancer-like symptoms. Aim of the study The present study aims at investigating 20 methanol extracts from 15 Cameroonian medicinal plants on a panel of human cancer cell lines, inclu…

0301 basic medicineNaucleaCell SurvivalAntineoplastic AgentsApoptosisMagnoliopsida03 medical and health sciencesPhytomedicine0302 clinical medicineMorus mesozygiaCell Line TumorDrug DiscoverymedicineHumansCameroonMedicinal plantsErythrinaMembrane Potential MitochondrialPharmacologyPlants MedicinalbiologyTraditional medicinePlant ExtractsCancerbiology.organism_classificationmedicine.diseaseDrug Resistance Multiple030104 developmental biologyDrug Resistance NeoplasmCaspases030220 oncology & carcinogenesisvisual_artCancer cellvisual_art.visual_art_mediumBarkReactive Oxygen SpeciesJournal of Ethnopharmacology
researchProduct

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

2020

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after …

0301 basic medicineNecrosisCentral nervous systemprimary progressive multiple sclerosisPrimary Progressive Multiple SclerosisCase ReportAnti-TNF-alpha therapylcsh:RC346-42903 medical and health sciences0302 clinical medicineadalimumabmedicineAdalimumabanti-TNF-alpha therapyDemyelinating DisorderAnti tnf α therapylcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industry030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct

Semaphorins in Adult Nervous System Plasticity and Disease

2021

Semaphorins, originally discovered as guidance cues for developing axons, are involved in many processes that shape the nervous system during development, from neuronal proliferation and migration to neuritogenesis and synapse formation. Interestingly, the expression of many Semaphorins persists after development. For instance, Semaphorin 3A is a component of perineuronal nets, the extracellular matrix structures enwrapping certain types of neurons in the adult CNS, which contribute to the closure of the critical period for plasticity. Semaphorin 3G and 4C play a crucial role in the control of adult hippocampal connectivity and memory processes, and Semaphorin 5A and 7A regulate adult neuro…

0301 basic medicineNervous systemsemaphorinsanimal structuresautismNeurosciences. Biological psychiatry. NeuropsychiatryReviewHippocampal formationBiologymultiple sclerosisExtracellular matrix03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineSemaphorinNeuroplasticitymedicineMultiple sclerosisPerineuronal netNeurogenesisCell Biologymedicine.diseaseschizophrenia030104 developmental biologymedicine.anatomical_structurenervous systemplasticityembryonic structuresAlzheimer’s disease; autism; epilepsy; multiple sclerosis; perineuronal net; plasticity; schizophrenia; semaphorinsepilepsysense organsperineuronal netbiological phenomena cell phenomena and immunityNeuroscienceAlzheimer’s disease030217 neurology & neurosurgeryNeuroscienceRC321-571
researchProduct

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

2016

Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group). The primary end point was progression-free survival.A prespecifie…

0301 basic medicineOncologyMaleAntigens CD38Drug ResistanceDexamethasoneIxazomibBortezomibchemistry.chemical_compound0302 clinical medicineRecurrenceMonoclonalAntineoplastic Combined Chemotherapy ProtocolsMedicineInfusions IntravenouElotuzumabInfusions IntravenousMultiple myelomaIsatuximabBortezomibMedicine (all)SLAMF7Antibodies MonoclonalGeneral MedicineMiddle Aged030220 oncology & carcinogenesisFemaleIntravenousMultiple MyelomaHumanmedicine.drugAdult; Aged; Antibodies Monoclonal; Antigens CD38; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance Neoplasm; Female; Humans; Infusions Intravenous; Male; Middle Aged; Multiple Myeloma; Recurrence; Medicine (all)AdultInfusionsmedicine.medical_specialtyAntibodiesDisease-Free Survival03 medical and health sciencesInternal medicineHumansAntigensAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryDaratumumabInterim analysismedicine.diseaseADP-ribosyl Cyclase 1Surgery030104 developmental biologychemistryDrug Resistance NeoplasmNeoplasmbusinessCD38The New England journal of medicine
researchProduct

Multidisciplinary surgical management of Cowden syndrome: Report of a case

2016

Cowden’s Syndrome (CS) is a rare congenital autosomal dominant disorder that affects around 1/200000 patients with an incomplete penetrance and variable expressivity, characterized by alterations in a tumor suppressor gene. A 14-year-old Caucasian male patient came to the attention of the authors complaining of palm nodules, gingival bleeding and painful pedunculated lesions on the lips and on the labial side of anterior sextants. After genetic investigation the final diagnosis of a Cowden Syndrome was made. The lesions were surgically removed under general anesthesia and no clinical signs of recurrence were found three months after surgical excision. Considering the severe symptoms of the …

0301 basic medicineOral papillomatosismedicine.medical_specialtyOdontologíaOral papillomatosisCancer predispositionSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciences0302 clinical medicineCancer predisposition; Case report; Early diagnosis; Multiple hamartoma syndrome; Oral papillomatosis; Dentistry (all)Case reportmedicineGeneral Dentistrybusiness.industryCancer predispositionMultiple hamartoma syndromeMultiple hamartoma syndrome030206 dentistryCowden syndromeEarly diagnosismedicine.diseaseCiencias de la saludPenetranceDermatologySurgery030104 developmental biologyMale patientDentistry (all)UNESCO::CIENCIAS MÃ DICASOdontostomatology for the Disabled or Special PatientsSurgical excision:CIENCIAS MÃ DICAS [UNESCO]businessJournal of Clinical and Experimental Dentistry
researchProduct

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

2018

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow microenvironment that favors immune escape. The Programmed Death-1 (PD-1) pathway is associated with the regulation of T cell activation and with the apoptotic pathways of effector memory T cells. Specifically, the binding with PD-1 ligand (PD-L1) on the surface of tumor plasma cells down-regulates T cell-proliferation, thus contributing to the immune escape of tumor cells. In relapsed and/or refr…

0301 basic medicinePD-L1lcsh:Immunologic diseases. AllergyDurvalumabMini ReviewT-LymphocytesT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationT cellsPembrolizumabmedicine.disease_causeB7-H1 Antigen03 medical and health sciences0302 clinical medicineBone Marrowimmune dysregulationPD-L1PD-1Tumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyImmune dysregulation; Multiple myeloma; PD-1; PD-L1; T cells; Animals; B7-H1 Antigen; Bone Marrow; Humans; Multiple Myeloma; Programmed Cell Death 1 Receptor; T-Lymphocytes; Tumor MicroenvironmentMultiple myelomabiologybusiness.industryImmune dysregulationmedicine.diseasemultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinCancer researchNivolumabbusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Pharmacogenomics of Scopoletin in Tumor Cells

2016

Drug resistance and the severe side effects of chemotherapy necessitate the development of novel anticancer drugs. Natural products are a valuable source for drug development. Scopoletin is a coumarin compound, which can be found in several Artemisia species and other plant genera. Microarray-based RNA expression profiling of the NCI cell line panel showed that cellular response of scopoletin did not correlate to the expression of ATP-binding cassette (ABC) transporters as classical drug resistance mechanisms (ABCB1, ABCB5, ABCC1, ABCG2). This was also true for the expression of the oncogene EGFR and the mutational status of the tumor suppressor gene, TP53. However, mutations in the RAS onc…

0301 basic medicinePharmaceutical ScienceATP-binding cassette transporterDrug resistancePharmacologycoumarinAnalytical Chemistrychemistry.chemical_compound0302 clinical medicineNeoplasmsDrug DiscoveryABC-transportermicroarraysNF-kappa BABCB5Drug Resistance MultipleGene Expression Regulation NeoplasticMolecular Docking SimulationDrug developmentChemistry (miscellaneous)030220 oncology & carcinogenesisherbal medicineMolecular MedicineSignal TransductionTumor suppressor geneProtein Array AnalysisBiologyArticlelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistrymultidrug resistanceCell Line TumorScopoletinHumansPhysical and Theoretical ChemistryTranscription factorScopoletinOncogenePlant ExtractsOrganic ChemistryTranscription Factor RelAphytotherapy030104 developmental biologyArtemisiachemistryDrug Resistance NeoplasmPharmacogeneticsCancer researchABC-transporter; cluster analysis; coumarin; herbal medicine; microarrays; multidrug resistance; phytotherapyATP-Binding Cassette Transporterscluster analysisMolecules
researchProduct

Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial dr…

2017

Abstract Introduction Malignacies are still a major public concern worldwide and despite the intensive search of new chemotherapeutic agents, treatment still remains a challenging issue. The present study was designed to evaluate the cytotoxicity of 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone (AMNQ) isolated from the bark of Milletia versicolor towards a panel of drug-sensitive and multidrug-resistant (MDR) cancer cell lines. Methods The resazurin reduction assay was used to evaluate the cytotoxicity of AMNQ against 9 drug-sensitive and multidrug-resistant (MDR) cancer cell lines. Cell cycle, mitochondrial membrane potential (MMP) and levels of reactive oxygen species were all analyze…

0301 basic medicinePharmaceutical ScienceApoptosisPharmacologyFlow cytometry03 medical and health sciences0302 clinical medicineCell Line TumorDrug DiscoverymedicineHumansCytotoxic T cellCytotoxicityMembrane Potential MitochondrialPharmacologymedicine.diagnostic_testPlant ExtractsChemistryCell CycleCancerCell cyclemedicine.diseaseAntineoplastic Agents PhytogenicDrug Resistance MultipleMultiple drug resistance030104 developmental biologyComplementary and alternative medicineDoxorubicinDrug Resistance NeoplasmApoptosisCaspases030220 oncology & carcinogenesisCancer cellCancer researchMolecular MedicineReactive Oxygen SpeciesNaphthoquinonesPhytomedicine
researchProduct

Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds

2018

Two major obstacles for successful cancer treatment are the toxicity of cytostatics and the development of drug resistance in cancer cells during chemotherapy. Acquired or intrinsic drug resistance is responsible for almost 90% of treatment failure. For this reason, there is an urgent need for new anticancer drugs with improved efficacy against cancer cells, and with less toxicity on normal cells. There are impressive examples demonstrating the success of natural plant compounds to fight cancer, such as Vinca alkaloids, taxanes, and anthracyclines. Artesunic acid (ARTA), a drug for malaria treatment, also exerts cytotoxic activity towards cancer cells. Multidrug resistance often results fro…

0301 basic medicinePharmaceutical ScienceDrug resistancePharmacologychemotherapyAnalytical Chemistry0302 clinical medicineartemisinin egonol thymoquinone hybridsDrug DiscoveryBenzoquinonesCytotoxic T cellCytotoxicitymedia_commonLeukemiaChemistryNaturwissenschaftliche FakultätArtemisininsDrug Resistance MultipleGene Expression Regulation NeoplasticMolecular Docking SimulationChemistry (miscellaneous)030220 oncology & carcinogenesisddc:540multi-drug resistanceMolecular Medicinemedicine.drugDrugCell Survivalmedia_common.quotation_subjectAntineoplastic AgentsArticlelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryCell Line TumormedicineHumansDoxorubicinPhysical and Theoretical Chemistrychemotherapy; multi-drug resistance; artemisinin egonol thymoquinone hybridsCell ProliferationOrganic ChemistryCancerSuccinatesmedicine.diseaseMultiple drug resistance030104 developmental biologyDoxorubicinDrug Resistance NeoplasmCancer cellATP-Binding Cassette TransportersMolecules
researchProduct